DAA-mediated HCV cure reduces HIV DNA levels in HCV/HIV coinfected people

J Virol. 2023 Dec 21;97(12):e0110523. doi: 10.1128/jvi.01105-23. Epub 2023 Dec 5.

Abstract

Antiretroviral therapy (ART) for human immunodeficiency virus (HIV) can control virus replication and prolong the life of people living with HIV (PLWH). However, the virus remains dormant within immune cells in what is called the HIV reservoir. Furthermore, 2.3 million PLWH are also coinfected with hepatitis C virus (HCV) and are at risk of developing chronic liver disease and cancer. HCV treatment with direct acting antivirals (DAA) can completely cure the infection in more than 95% of treated individuals and improve their long-term health outcomes. In this study, we investigated how HCV treatment and cure affect the HIV reservoir. We demonstrate the beneficial impact of DAA treatment as it reduces the HIV reservoirs in particular in people infected with HCV before HIV. These results support the need for early ART and DAA treatment in HIV/HCV coinfections.

Keywords: CD4+ T-cells; HIV viral reservoir; direct acting antivirals; hepatitis C virus.

MeSH terms

  • Antiviral Agents* / pharmacology
  • Antiviral Agents* / therapeutic use
  • Coinfection* / drug therapy
  • HIV / physiology
  • HIV Infections* / complications
  • HIV Infections* / drug therapy
  • Hepacivirus / physiology
  • Hepatitis C* / complications
  • Hepatitis C* / drug therapy
  • Hepatitis C, Chronic* / complications
  • Hepatitis C, Chronic* / drug therapy
  • Humans

Substances

  • Antiviral Agents